These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 7339639)

  • 21. Plasma level and effect of low-dose haloperidol in acute psychosis.
    Bleeker JA; Dingemans PM; Frohn-de Winter ML; van de Slooten EP
    Psychopharmacol Bull; 1984; 20(2):317-9. PubMed ID: 6728996
    [No Abstract]   [Full Text] [Related]  

  • 22. Computerized EEG study on drug-induced extrapyramidalism in schizophrenic patients.
    Saito M; Kita S; Kagono Y; Suitsu N; Honda Y
    Electroencephalogr Clin Neurophysiol Suppl; 1982; 36():524-37. PubMed ID: 6962040
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparison of haloperidol plasma concentrations between twice-a-day and once-a-day dosing in Chinese schizophrenic patients.
    Lin SK; Chen CH; Chang WH
    J Formos Med Assoc; 1993 Sep; 92(9):832-4. PubMed ID: 7904867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of carbamazepine on plasma haloperidol levels.
    Jann MW; Ereshefsky L; Saklad SR; Seidel DR; Davis CM; Burch NR; Bowden CL
    J Clin Psychopharmacol; 1985 Apr; 5(2):106-9. PubMed ID: 3988968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ratio of serum prolactin to haloperidol and early clinical outcome in acute psychosis.
    Swigar ME; Jatlow PI; Goicoechea N; Opsahl C; Bowers MB
    Am J Psychiatry; 1984 Oct; 141(10):1281-3. PubMed ID: 6486269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug holidays and serum haloperidol levels in schizophrenic patients.
    McMillan DE; Fody EP; Couch L; Harrison RH; Newton JE; Reese WG
    J Clin Psychiatry; 1986 Jul; 47(7):373-4. PubMed ID: 3722135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of parenteral administration of haloperidol and chlorpromazine in man. I. Normal subjects: quantitative EEG and subjective response.
    Pfeiffer CC; Goldstein L; Murphree HB
    J Clin Pharmacol J New Drugs; 1968; 8(2):79-88. PubMed ID: 5240366
    [No Abstract]   [Full Text] [Related]  

  • 28. Correlation between steady-state plasma concentrations (Css) of bromperidol and haloperidol.
    Yasui N; Otani K; Kondo T; Suzuki A; Furukori H; Kaneko S; Inoue Y
    Prog Neuropsychopharmacol Biol Psychiatry; 1998 Apr; 22(3):485-92. PubMed ID: 9612845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review of haloperidol blood level and clinical response: looking through the window.
    Volavka J; Cooper TB
    J Clin Psychopharmacol; 1987 Feb; 7(1):25-30. PubMed ID: 3546403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haloperidol plasma levels and clinical response: a therapeutic window relationship.
    Van Putten T; Marder SR; Mintz J; Poland RE
    Am J Psychiatry; 1992 Apr; 149(4):500-5. PubMed ID: 1554036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroleptic radioreceptor activity and clinical outcome in schizophrenia.
    Contreras S; Alexander H; Faber R; Bowden C
    J Clin Psychopharmacol; 1987 Apr; 7(2):95-8. PubMed ID: 3584527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms.
    Neborsky RJ; Janowsky DS; Perel JM; Munson E; Depry D
    J Clin Psychiatry; 1984 Jan; 45(1):10-3. PubMed ID: 6363395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of route of administration on haloperidol plasma levels in psychotic patients.
    Bianchetti G; Zarifian E; Poirier-Littre MF; Morselli PL; Deniker P
    Int J Clin Pharmacol Ther Toxicol; 1980 Jul; 18(7):324-7. PubMed ID: 7429678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Standard and high doses of haloperidol. Clinical, pharmacokinetic and pharmacodynamic aspects].
    Schilkrut R; Haverbeck C; Duran E; Delgado S; Kohen P; Birkner R; Katz I
    Acta Psiquiatr Psicol Am Lat; 1981; 27(4-5):315-24. PubMed ID: 7348089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Electroencephalographic changes and other indices of neurotoxicity with haloperidol-lithium therapy.
    Saran A; Addy O; Foliart RH; Schubert DS; Halaris A
    Neuropsychobiology; 1989; 20(3):152-7. PubMed ID: 2569693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic window for plasma haloperidol in acute schizophrenic psychosis.
    Extein I; Pottash AL; Gold MS
    Lancet; 1983 May; 1(8332):1048-9. PubMed ID: 6133089
    [No Abstract]   [Full Text] [Related]  

  • 37. Haloperidol concentrations in saliva and serum: determination by the radioimmunoassay method.
    Yamazumi S; Miura S
    Int Pharmacopsychiatry; 1981; 16(3):174-83. PubMed ID: 7198629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of clinical response (PANSS) and plasma levels of haloperidol and reduced haloperidol in schizophrenia.
    Leroux JM; Elia E; Jacquet M; Pommery J; Levron JC; Bouhours P; Erb F; Sechter D
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Mar; 18(2):347-53. PubMed ID: 8208983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum haloperidol and neuroleptic receptor levels in chronic psychosis.
    Cannon DJ; McMillan DE; Newton JE; Fody EP; Metzer WS; Claybrook M; Couch L; Paige SR
    Ann Clin Lab Sci; 1988; 18(5):378-83. PubMed ID: 3178137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distribution and metabolism of neuroleptic drugs. I. Pharmacokinetics of haloperidol.
    Lewi PJ; Heykants JJ; Allewijn FT; Dony JG; Janssen PA
    Arzneimittelforschung; 1970 Jul; 20(7):943-8. PubMed ID: 5536066
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.